| DermTech is a molecular diagnostic company developing and marketing non-invasive genomics tests to aid in the diagnosis and management of various skin conditions, including skin cancer, inflammatory diseases, and aging-related conditions. Co.'s focus is skin cancer. Co. provides the DermTech Melanoma Test for the early detection of melanoma and is developing a product for non-melanoma skin cancer. Co. is also working on products to assess precancerous genomic changes associated with sun UV exposure to the skin. Co. has additional skin cancer product offerings, including for non-melanoma skin cancers (basal cell and squamous cell cancers), under development. We show 8 historical shares outstanding datapoints in our coverage of DMTK's shares outstanding history.|
Understanding the changing numbers of DMTK shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like DMTK versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching DMTK by allowing them to research DMTK shares outstanding history
as well as any other stock in our coverage universe.